Investigational drug · Phase 2
LSAM-Cisplatin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diffuse Midline Glioma (DMG), Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "LSAM-Cisplatin"
First trial start
2026
Dec 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LSAM-Cisplatin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diffuse Midline Glioma (DMG)
- Diffuse Intrinsic Pontine Glioma (DIPG)
- Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LSAM-Cisplatin" as an intervention, largest first.
- Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of ResponseNot yet recruiting
NanOlogy, LLC (doing business as Intryx Therapeutics, LLC)Industry
NCT07767110 · 20 participants (planned) · Start Dec 2026 · Primary completion Dec 2029
Drug: LSAM-Cisplatin · For: Diffuse Midline Glioma (DMG); Diffuse Intrinsic Pontine Glioma (DIPG); Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.